5
GEM045, Autotaxin Inhibitor to treat NASH
GEMSEKI
Small molecule
Metabolic disease
Pre-Clinical
Lysophospholipid signaling is emerging as a regulator of pathophysiological responses, especially fibrosis. Autotaxin (ATX), a secreted lysophospholipase D (lysoPLD), is responsible for extracellular lysophosphatidic acid (LPA) production. LPA activates multiple G-protein mediated signal transduction pathways leading to responses including the production of pro-inflammatory signals including the stimulation of fibroblast accumulation. Pharmacologic targeting of the ATX/LPA axis using autotaxin inhibitor attenuated fibrotic disease development.
